1. Home
  2. Companies
  3. PAR
  4. Material Events

Paradigm Biopharmaceuticals (ASX:PAR) — Material Events

ASX:PAR · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 14 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Paradigm Biopharma Secures A$45m to Power Phase 3 Knee OA Trial Through Key Interim AnalysisHigh
Paradigm Biopharma hits 50% dosing in Phase 3 OA trial, secures A$45m funding, targets August interim analysis
27 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·85
Paradigm Biopharma Advances Phase 3 Trial, Secures $50M Funding RunwayMedium
Paradigm Biopharma starts Phase 3 dosing, secures funding and expands osteoarthritis portfolio
30 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
Paradigm Accelerates Phase 3 Trial with $41M Funding and New Osteoarthritis PipelineMedium
Paradigm advances Phase 3 OA trial with US$27m funding and pipeline expansion
29 July 2025 ·Quarterly Activities Report & Appendix 4C ·85
Paradigm Surpasses Target in Phase 3 Osteoarthritis Trial EnrolmentMedium
Paradigm completes enrolment in Phase 3 osteoarthritis trial, on track for 2027 results
15 June 2026 ·Clinical Trial Update ·85
Paradigm Biopharma Advances Phase 3 OA Trial, Secures $41M Funding, Expands PipelineHigh
Paradigm Biopharma advances Phase 3 OA trial, secures $41M funding, expands pipeline with Pentacoxib™ acquisition
29 Aug 2025 ·Annual Report ·85
Paradigm Advances Global Phase 3 Knee OA Trial with New Sites and Strong FundingMedium
Paradigm advances Phase 3 knee osteoarthritis trial with strong recruitment and funding; publishes Phase 2 biomarker study
30 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·80
Paradigm Reaches Halfway Mark in Phase 3 Osteoarthritis Trial Ahead of August ReadoutMedium
Paradigm Hits 50% Enrolment in Phase 3 Osteoarthritis Trial, Interim Analysis Due August 2026
31 Mar 2026 ·Clinical Trial Progress Update ·80
Paradigm Biopharma Accelerates Phase 3 Trial Ahead of Mid-2026 Interim AnalysisMedium
Paradigm Biopharma reports increased half-year loss amid Phase 3 trial progress and prepares for pivotal interim analysis
27 Feb 2026 ·Appendix 4D Half-year report ·80
Paradigm Biopharma Advances Phase 3 Trial with US and Australia Dosing MilestoneMedium
Paradigm Biopharma doses Phase 3 trial participants in US and Australia, on track for mid-2026 interim analysis
30 Sept 2025 ·Clinical Trial Progress Update ·80
Paradigm’s PPS Study in Dogs Signals Promising Osteoarthritis BreakthroughMedium
Paradigm publishes study showing sustained benefits of PPS in canine osteoarthritis, supporting human Phase 3 program
11 Feb 2026 ·Scientific Publication Announcement ·80
Paradigm Biopharma Raises $21.375 Million in Oversubscribed Share Purchase PlanMedium
Paradigm Biopharma raises $21.375 million through oversubscribed SPP and Placement
1 June 2026 ·Capital Raising ·80
Paradigm and AVet Health Ink Exclusive Veterinary Licensing Deal for Oral Osteoarthritis Therapy in ANZMedium
Paradigm and AVet Health ink exclusive veterinary licensing deal for oral osteoarthritis therapy in ANZ
9 Feb 2026 ·Licensing Agreement ·80
Paradigm’s Phase 2 Study Validates iPPS Impact on Osteoarthritis BiomarkersMedium
Paradigm’s Phase 2 iPPS Biomarker Study Published, Validating Osteoarthritis Treatment Mechanism
28 Jan 2026 ·Scientific Publication Announcement ·75
Paradigm Biopharma Secures US$5M to Accelerate Global Phase 3 Trial ExpansionMedium
Paradigm Biopharma draws US$5M tranche to fund Phase 3 knee osteoarthritis trial expansion
17 Nov 2025 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.